Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1083 | 994 | 1242 | 1079 | 1477 | 1720 |
Fund Return | 8.35% | -0.55% | 24.16% | 2.58% | 8.11% | 5.57% |
Place in category | 262 | 271 | 162 | 174 | 68 | 84 |
% in Category | 35 | 40 | 22 | 30 | 10 | 23 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Northern Stock Index | 15.31B | 20.90 | 8.99 | 12.89 | ||
Northern International Equity Index | 4.87B | 6.95 | 2.73 | 5.14 | ||
Northern Mid Cap Index | 2.23B | 12.68 | 5.07 | 9.70 | ||
Northern Global Sustainability Inde | 2.01B | 15.92 | 6.01 | 9.90 | ||
Northern Emerging Markets Equity In | 1.83B | 10.83 | -2.10 | 2.89 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Vanguard Total Intl Stock Index Inv | 204.36B | 8.15 | 1.40 | 4.88 | ||
Vanguard Total Intl Stock Index Adm | 75.61B | 8.18 | 1.45 | 4.94 | ||
Fidelity International Index Inst | 52.9B | 6.96 | 2.81 | 5.35 | ||
Fidelity Series Global ex US Index | 48.18B | 8.52 | 1.64 | 4.77 | ||
Strategic Advisers International I | 42.32B | 8.45 | 1.91 | 6.07 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
ICON PLC | IE0005711209 | 2.15 | 214.25 | +0.70% | |
Novo Nordisk B | DK0062498333 | 1.96 | 750.9 | +4.03% | |
AstraZeneca | GB0009895292 | 1.52 | 10,474.0 | +4.09% | |
Aon | IE00BLP1HW54 | 1.39 | 386.21 | +0.94% | |
SAP | DE0007164600 | 1.33 | 225.900 | +0.53% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Neutral | Neutral | Buy |
Technical Indicators | Strong Sell | Strong Sell | Strong Buy |
Summary | Sell | Sell | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review